Salvatore Albani's Research Focus
Salvatore Albani's Research Report
Diseases characterized by chronic inflammation are notoriously difficult to treat. Frequently, we don’t know what causes such diseases, nor how to cure them. Therapies on the market achieve a level of efficacy in a percentage of patients, and their mechanisms of action are not clear. Dr. Albani has dedicated his career to unraveling some of these mysteries through translational research.
Our lab seeks to translate basic science into tangible clinical practices and therapeutic options to improve the quality of patients' lives.
Our research platforms have generated over 80 patents to-date. More importantly, our research has contributed to a greater body of knowledge that will ultimately help develop better treatments, better protocols and improve human health.
The Albani laboratory designs and exploits tools for the manipulation of adaptive immunity for therapeutic purposes:
What if you could retrain the immune system to recognize itself again?
That’s the concept behind a pool of short synthetic pan HLA-DR binder peptides. These peptides can be used as oral immunomodulators. Clinical applications include rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, type 1 diabetes, and juvenile idiopathic arthritis. The technology has been developed by Dr. Albani from concept to conclusion of a Phase II trial in rheumatoid arthritis, showing safety and clinical efficacy, and to pre-IND for multiple sclerosis and inflammatory bowel disease.
(Nature Medicine 1995/2009, Nature Reviews Rheumatology 2011, JCI 1992/1997, PNAS 2004, Lancet 2005/2011, A&R 2006/2007/2009)
Manipulation of T cells using artificial antigen-presenting cells:
Sometimes there is not enough of a good thing.
Example: antigen-specific T cells. The T-cell capture technology enables identification, isolation and modulation of T cells, in a polyclonal and antigen-specific fashion. Applications include immunotherapy of cancer and treatment of infections in an immunocompromised host.
(Nature Medicine 2000, JI 2005. Blood 2006, A&R 2007, Haematologica 2008)
Reverse Translational Immunomics Platform:
Putting the pieces together to generate a more complete picture.
Immunomics is the integration of multiplex phenotypical assays (FACS ARIA II, multiplex TaqMan and functional assays). We use the Immunomics platform to dissect: i) function and phenotype of individual sub-types of immune cells; and ii) their relative functional relationship also in association with treatment and clinical status. Multiple stratifications by FACS enable identification of subpopulations of immune cells which simultaneously express a given cluster of molecules. TaqMan provides the quantitation aspect of the analysis. TaqMan also enables targeting of a large number of molecules.